FAG
ACAD icon

Fortitude Advisory Group’s Acadia Pharmaceuticals ACAD Stock Holding History

Fortitude Advisory Group’s Portfolio ACAD Stock Details ACAD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-215
Closed -$5K – 211
2022
Q1 		$5K Hold
215
– – ﹤0.01% 1148
2021
Q4 		$5K Buy
+215
New +$4.32K ﹤0.01% 1172

Other funds holding ACAD

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Fortitude Advisory Group's ACAD Position: Q2 2022 in Review

Fortitude Advisory Group sold out of Acadia Pharmaceuticals (ACAD) in Q2 2022, closing a stake of 215 shares — an estimated $5K sold.

Fortitude Advisory Group first reported a position in ACAD in Q4 2021 and held it in 2 quarters. The position peaked at $5K in Q1 2022. 246 funds tracked by Wall St. Rank hold ACAD as of Q2 2022.

  • Fortitude Advisory Group reported no remaining Acadia Pharmaceuticals position as of Q2 2022 after selling out during the quarter.
  • Fortitude Advisory Group sold 215 Acadia Pharmaceuticals shares in Q2 2022, an estimated $5K.
  • Fortitude Advisory Group first reported a position in Acadia Pharmaceuticals in Q4 2021 and held it in 2 quarters.
  • Fortitude Advisory Group's Acadia Pharmaceuticals position peaked at $5K in Q1 2022.
  • 246 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q2 2022.

Based on Fortitude Advisory Group's 13F filing for Q2 2022, filed 16 Aug 2022.